Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cofrogliptin (HSK7653) Add-on to Metformin in Type 2 Diabetes
NCT04564872Phase 3Completed
- Sponsor
- Sichuan Haisco Pharmaceutical Co., Ltd.
- Start
- Nov 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cofrogliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sichuan Haisco Pharmaceutical Co., Ltd. Primary endpoint: HbA1c Change From Baseline at Week 24. Started Nov 2020; status: completed.
02
Drugs
cofrogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04564872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564872.